Currently, Zynlonta is the only anti-CD19 drug approved ADC for relapsed/refractory DLBCL as a single agent (Zammarchi et al., 2018; Fu et al., 2022). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.